scholarly journals Targeting C-domain of Angiotensin Converting Enzyme and Nerprilysin as a Potential New Therapeutic Strategy in Hypertension

2021 ◽  
Vol 69 ◽  
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Therapeutic Strategy ◽  
Converting Enzyme

scholarly journals Angiotensin converting enzyme 2 activation: a novel potential Covid-19 therapeutic strategy

2020 ◽  
Author(s):  
Haidy E. Michel
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Strategy ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) downregulates pulmonary ACE2 protein, resulting in pneumonia. Thus, increasing ACE2 activation may serve to both neutralize the virus and rescue cellular ACE2 activity protecting the lung from damage. Diminazene, an ACE2 activator, is suggested to be a novel tentative SARS-CoV-2 therapeutic.

Melatonin, cardiovascular disease and COVID-19: A potential therapeutic strategy?

2020 ◽  
Vol 3 (3) ◽  
pp. 318-321 ◽  
Author(s):  
Alberto Dominguez-Rodriguez ◽  
Pedro Abreu-Gonzalez ◽  
Paul E Marik ◽  
Russel J Reiter
Keyword(s):  
Reactive Oxygen Species ◽  
Cardiovascular Disease ◽  
Endothelial Dysfunction ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Strategy ◽  
Oxygen Species ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Ros Formation ◽  
Membrane Bound

The mechanism for SARS-CoV-2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. SARS-CoV-2 induced endothelial dysfunction and cardiovascular injury are probably initiated by increases in the phosphorylation levels of JAK2 and STAT3 and resultant reactive oxygen species (ROS) formation. These pathological alterations are speculated to be strikingly reversed by melatonin

scholarly journals Angiotensin converting enzyme 2 activation: a novel potential Covid-19 therapeutic strategy

2020 ◽  
Author(s):  
Haidy E. Michel
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Strategy ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) downregulates pulmonary ACE2 protein, resulting in pneumonia. Thus, increasing ACE2 activation may serve to both neutralize the virus and rescue cellular ACE2 activity protecting the lung from damage. Diminazene, an ACE2 activator, is suggested to be a novel tentative SARS-CoV-2 therapeutic.

Sign in / Sign up

Export Citation Format

Share Document